DBV Technologies S.A.

NASDAQ:DBVT

Biotechnology

Healthcare
$9.99 -0.95%

-$0.16 today

Market cap
$238.98M
Beta
-0.22
P/E (TTM)
-8.3
EPS (TTM)
-$0.39
52W Low $8.50High $26.19

Volume 0.17M

Average 0.24M

DBVT Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

DBV Technologies S.A.NASDAQ: DBVT

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $33.4M rose 55.5% year over year, ahead of the +42.2% change in trailing-twelve-month research & development. Sequentially, it rose 1.5% from the prior quarter. Over 3 fiscal years it compounded at +15.6% a year.

Context

  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +55.5% holds above the trailing-twelve-month pace of +42.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$33.4M+1.5% QoQ
Last fiscal yearDec 2025
$116.68M+29.8% YoY
LTMMar 2026
$124.71M+42.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+55.5%——
1 year+29.8%——
3-year CAGR+15.6%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
116.68M USD
Year-over-year change
+29.8%
4-year CAGR
+13.5%

Research & Development vs competitors

How DBVT compares with its peers on the latest reported figures

  • DBVT's LTM Mar 2026 research & development of $124.71M is the 3rd highest of the 11 companies compared; the peer median is $64.55M.
  • Its year-over-year change of +42.2% is the 3rd highest of 10, against a peer median of +5.0%.
  • Over three fiscal years its annual growth of +15.6% compares with a peer median of +16.9%.
DBVT Competitors Peer median
Research & Development for DBVT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANNXAnnexon, Inc.LTM Mar 2026$172.31M +17.5%+18.0%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$152.7M +75.7%+85.3%—
DBVTDBV Technologies S.A.LTM Mar 2026$124.71M +42.2%+15.6%—
ENGNenGene Holdings Inc.LTM Apr 2026$98.75M +56.7%+82.8%—
CLLSCellectis S.A.LTM Mar 2026$94.68M +5.0%-1.4%139.0%
ALTAltimmune, Inc.LTM Mar 2026$66.77M -12.8%-2.0%185483.3%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$62.33M -17.5%+9.1%—
KRROKorro Bio, Inc.LTM Mar 2026$58.79M -15.8%+15.8%1530.1%
ANROAlto Neuroscience, Inc.LTM Mar 2026$55.94M +19.0%+24.4%—
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$28.47M —+131.7%—
AMRNAmarin Corporation plcLTM Mar 2026$18.45M -6.9%-13.3%8.6%
Peer median (excluding DBVT) $64.55M+5.0%+16.9%834.6%

Competitors are the stored peer set for DBVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.71M4.8M15.73M00
Cost of Revenue9.27M20.3M06.81M17.67M
Gross Profit(3.57M)(15.5M)15.73M(6.81M)(17.67M)
Gross Margin-62.5%-322.9%100.0%——
Research & Development70.34M75.5M60.22M89.9M116.68M
Selling, General & Admin23.83M17.56M31.94M23.81M28.28M
Operating Expenses93.93M101.48M92.16M113.71M147.06M
Depreciation & Amortization8.38M20.3M13.16M6.81M7.73M
EBITDA(91.16M)(76.68M)(63.27M)(110.99M)(139.32M)
EBITDA Margin-1597.0%-1597.5%-402.3%——
Operating Income(98.61M)(96.63M)(76.43M)(120.53M)(147.06M)
Operating Margin-1727.6%-2013.1%-486.0%——
Interest Income521K406.29K3.71M2.73M601.86K
Interest Expense690K427K000
Other Income / Expenses424K427K3.71M2.73M600K
Income Before Tax(98.19M)(96.2M)(72.72M)(117.8M)(146.46M)
Pre-Tax Margin-1720.2%-2004.3%-462.4%——
Income Tax Expense(381K)70K7K(4.08M)491K
Net Income(97.81M)(96.3M)(72.73M)(113.72M)(146.95M)
Net Margin-1713.5%-2006.3%-462.4%——
EPS (Basic)(1.80)(1.25)(0.75)(1.20)(1.70)
EPS (Diluted)(1.80)(1.25)(0.75)(1.20)(1.70)
Weighted Avg Shares55.1M77.38M95.12M96.17M86.4M
Weighted Avg Shares (Diluted)55.1M77.38M95.12M96.17M86.4M

DBV Technologies S.A.

NASDAQ:DBVT

Intrinsic Alpha fair value

Locked

Current Price

$9.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.